MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea · Delayed Price · Currency is KRW

117.00

+27.00 (30.00%)

At close: Nov 12, 2026

Market Cap	2.47B -96.3%
Revenue (ttm)	10.46B -14.0%
Net Income	-13.80B
EPS	-702.10
Shares Out	21.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,185,751
Open	100.00
Previous Close	90.00
Day's Range	97.00 - 117.00
52-Week Range	82.00 - 3,788.00
Beta	0.85
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1999

Employees 47

Stock Exchange KOSDAQ

Ticker Symbol 142760

Full Company Profile

Financial Performance

In 2025, MOA Life Plus's revenue was 11.22 billion, a decrease of -28.24% compared to the previous year's 15.63 billion. Losses were -13.05 billion, 88.6% more than in 2024.

Financial Statements